Multiple Myeloma | Specialty

MRD Timepoints in CLL

August 29th 2017

CLL: Value of MRD Testing

August 29th 2017

Goals of Therapy in CLL

August 29th 2017

Published Data Demonstrate Efficacy of Carfilzomib in Myeloma

August 24th 2017

Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma

Kumar Discusses Latest Developments in Myeloma

August 17th 2017

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

August 9th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

August 4th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Expert Discusses Rapid Advances, Next Steps in Multiple Myeloma

August 4th 2017

Peter Voorhees, MD, discusses treatments for both newly diagnosed and relapsed patients with multiple myeloma.

XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma

August 3rd 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Dr. Friend on the Importance of Work-up for Patients With Multiple Myeloma

August 3rd 2017

Reed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of appropriate work-ups for patients with multiple myeloma.

Usmani Discusses Emergence of CAR T-Cell Therapy in Myeloma

August 1st 2017

Saad Z. Usmani, MD, discusses recent multiple myeloma data, the potential role of CAR T-cell therapy, and what therapeutic advancements the community can expect in the remainder of 2017.

Plethora of Novel Agents Transforming Outcomes in Multiple Myeloma

July 28th 2017

Rachid Baz, MD, discusses the change in risk factors for select treatments, the impact of daratumumab, and current sequencing questions in multiple myeloma.

Myeloma Expert Stresses Significance of Appropriate Diagnostic Work-up

July 28th 2017

Reed Friend, MD, discusses the revised steps in diagnosing patients with multiple myeloma and prognostic factors, as well as existing challenges and hopes for the field’s future.

Proteasome Inhibitors Paving Promising Path for Myeloma Treatment

July 17th 2017

Kenneth H. Shain, MD, discusses the emergence of proteasome inhibitors in multiple myeloma and whether these agents will be best used as monotherapy or in combination regimens.

Myeloma Trial Explores Optimal Induction, Maintenance Regimens

July 17th 2017

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

Amgen Files sNDAs for Carfilzomib to Treat Multiple Myeloma in Europe, US

July 14th 2017

Amgen has announced that it has submitted supplemental New Drug Applications (sNDA) in the United States and Europe based on data from 2 phase III studies showing carfilzomib (Kyprolis) improves overall survival (OS) for patients with relapsed/refractory multiple myeloma.

Carfilzomib Combo Extends Survival for Myeloma in Final ASPIRE Analysis

July 13th 2017

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma.

Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

July 12th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6th 2017

The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.

Dr. Kumar Discusses Ixazomib in Multiple Myeloma

July 5th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.